### WEST PHARMACEUTICAL SERVICES INC Form DEFA14A April 14, 2017

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

#### **SCHEDULE 14A**

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Preliminary Proxy Statement

Filed by the Registrant x

Check the appropriate box:

o

Filed by a Party other than the Registrant o

Definitive Proxy Statement		
Definitive Additional Materials		
Soliciting Material Pursuant to	§240.14a-12	
West Pharmaceutical Services, Inc.		
(Name of Registrant as Specified In Its Charter)		
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)		
ng Fee (Check the appropriate box):		
*	os 14s 6(i)(1) and 0.11	
	Title of each class of securities to which transaction applies:	
(-)	The of their thing of securities to which thinkness approxi-	
(2)	Aggregate number of securities to which transaction applies:	
(3)	Per unit price or other underlying value of transaction computed	
	pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):	
	ining fee is calculated and state now it was determined).	
(4)	Proposed maximum aggregate value of transaction:	
(5)	Total fee paid:	
Fee paid previously with preliminary materials.		
o Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the		
	ous filing by registration statement number, or the Form or Schedule and	
	Amount Previously Paid:	
	Amount Heviously Fuld.	
(2)	Form, Schedule or Registration Statement No.:	
(3)	Filing Party:	
(4)	Date Filed:	
	Definitive Additional Materials Soliciting Material Pursuant to  West Pharmace (Name of Registrant a   (Name of Person(s) Filing Proxy Soliciting Proxy Solicit	

Persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

West Pharmaceutical Services, Inc. 530 Herman O. West Drive Exton, PA 19341 www.westpharma.com

April 13, 2017

Dear Shareholder:
We revised the proxy card for shareholders to use in conjunction with our 2017 Annual Meeting of Shareholders to take place on May 2, 2017. The sample proxy card distributed on March 22, 2017 and the voting options previously provided at www.proxyvote.com did not reflect the majority voting standard in our Bylaws. The majority vote requirement and treatment of abstentions is accurately described in our proxy statement on page 5.
We have included a revised proxy card with this letter and have revised the voting options at www.proxyvote.com. Consistent with the majority voting standard, the revised proxy card gives you the option to vote For, Against or Abstain with respect to each director individually. We are using Abstain , instead of Withhold to be more consistent with our Bylaws as well.
If you have not yet voted, please discard the previously provided proxy card and use the enclosed revised proxy card to vote your shares by mail, or follow the instructions on the revised proxy card to vote via the internet or by telephone.
If you have already voted on www.proxyvote.com and do not change your vote or you use the prior proxy card, a vote for a director indicated as Withhold will be treated as an Against vote for all purposes at the meeting. We encourage shareholders who intended to vote abstain or intended to withhold their vote rather than vote Against to revise their vote on www.proxyvote.com or complete a new proxy card by checking the box for Abstain.
The changes to the proxy card only impact the election of directors. There are no changes to the voting for the other proposals up for consideration at the meeting.
If you have any questions, or need assistance in voting your shares, please contact me at 610-594-3319.
As always, your vote is important, and we appreciate your attention to this matter. We apologize for any inconvenience.
Sincerely,

George L. Miller

Senior Vice President, General Counsel and Secretary

West Pharmaceutical Services, Inc. • Global Partners with Daikyo Seiko. Ltd. and The West Company Mexico S.A. de C.V.